Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00321503
Other study ID # 1345-2005
Secondary ID DX-1 for LPR
Status Completed
Phase N/A
First received May 2, 2006
Last updated December 6, 2013
Start date May 2006
Est. completion date May 2007

Study information

Verified date December 2013
Source Emory University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This study is a test of how well a new FDA-approved device is for diagnosing a condition known as laryngopharyngeal reflux (LPR). The device, which measures pH of the air in the upper throat, will be compared to several other methods for diagnosing laryngopharyngeal reflux.


Description:

It is estimated that up to 50% of patients with voice disorders and 4-10% of patients seen in otolaryngology practice experience laryngopharyngeal reflux (LPR). LPR has been implicated in the pathogenesis of numerous laryngeal disorders, including subglottic stenosis, laryngeal carcinoma, laryngeal contact ulcers, laryngospasm, and vocal cord nodules. In the pediatric population, it has been associated with asthma, sinusitis, and otitis media. Common symptoms include chronic and intermittent hoarseness, vocal fatigue, globus pharyngeus, cough, postnasal drip, chronic throat clearing, and dysphagia.

Like gastroesophageal reflux disease (GERD), the etiology of LPR is linked to esophageal sphincter dysfunction. In GERD, the lower esophageal sphincter (LES) is involved, whereas in LPR, the pathology results from upper esophageal sphincter (UES) dysfunction. However, diagnosis of LPR is more challenging than that of GERD. The classic reflux-like symptoms of heartburn and regurgitation are often absent in LPR.

The most widely used diagnostic modality for LPR is symptomatic response to treatment, including twice daily proton pump inhibitor (PPI) or H2 blocker therapy for several months. However, the use of a therapeutic modality to make a diagnosis clearly carries disadvantages, including potentially unnecessary exposure to a drug's side effect profile and lengthy time to diagnosis. Another diagnostic instrument is the reflux symptom index (RSI), a validated nine-item questionnaire assessing LPR symptoms. However, LPR symptoms are fairly nonspecific, also appearing in autoimmune and behavior disorders. Lastly, a 24-hour triple-pH probe may be the best objective test diagnosing LPR. However, this method is poorly tolerated by patients and difficulty with ease of administration limits its routine use. To date, we have remained in search of a minimally invasive and specific test for LPR.

In this study, we will investigate the use of a newly developed oropharyngeal pH probe for detecting aerosolized acid as an accurate and minimally invasive diagnostic instrument for LPR. This device has previously been shown to correlate to lower esophageal, upper esophageal, and lower pharyngeal pH as measured by a 24-hour triple channel bifurcated pH probe [ACG Poster session by Dr. G Wiener]. The number of oropharyngeal aerosolized acid reflux events and acid exposure times will be compared to RSI before and after twice daily proton pump inhibitor therapy. In addition, the correlation between acid reflux events and acid exposure times as measured by the Dx probe will be more rigorously compared to that measured by a triple pH probe.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date May 2007
Est. primary completion date May 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility INCLUSION CRITERIA:

Group 1 (negative control):

- RSI = 13

- No history of voice or swallowing disorders

- No active voice or swallowing disorders

- No history of heartburn, regular indigestion, and no prior or current diagnosis of GERD

Groups 2 and 3 (experimental group):

- Clinical symptoms consistent with LPR as measured by an RSI > 13.

- No other voice or swallowing pathology on clinical exam

EXCLUSION CRITERIA:

- Regular treatment with an H2 blocker or proton pump inhibitor (PPI)

- History of laryngeal/pharyngeal surgery

- Any planned treatment of the larynx/pharynx other than treatment for LPR

- Smoking

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Emory Voice Center Atlanta Georgia

Sponsors (3)

Lead Sponsor Collaborator
Emory University AstraZeneca, Respiratory Technology Corporation

Country where clinical trial is conducted

United States, 

References & Publications (2)

Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002 Jun;16(2):274-7. — View Citation

Merati AL, Lim HJ, Ulualp SO, Toohill RJ. Meta-analysis of upper probe measurements in normal subjects and patients with laryngopharyngeal reflux. Ann Otol Rhinol Laryngol. 2005 Mar;114(3):177-82. Review. — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT06205446 - Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction N/A
Completed NCT02552966 - Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin N/A
Completed NCT01450748 - Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux Phase 3
Recruiting NCT04827355 - Reflux Band in Laryngopharyngeal Reflux N/A
Not yet recruiting NCT03455803 - Effect of CPAP Therapy on LPR Among Patients With OSAS N/A
Withdrawn NCT02530879 - Comparison of Voice Therapy and Antireflex Therapy in LPR Phase 4
Completed NCT01854970 - Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux N/A
Terminated NCT01317472 - The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux N/A
Completed NCT01880892 - Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy N/A
Completed NCT02183961 - Three Methods Used in the Diagnosis of EER in Children With OME N/A
Not yet recruiting NCT01328652 - Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Phase 4
Not yet recruiting NCT04383262 - Lexiva for the Treatment of LPR Phase 3
Recruiting NCT04984304 - Individualized Diagnosis and Treatment of Extraesophageal Reflux in Patients With Chronic Cough N/A
Withdrawn NCT03463395 - Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux N/A
Completed NCT00864396 - Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux Phase 1
Completed NCT03619811 - Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease N/A
Recruiting NCT05879029 - Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD Phase 4
Recruiting NCT05204303 - LPR Fluorescence Pilot
Terminated NCT01777854 - Anti-reflux Control to Decrease Post Tonsillectomy Pain Phase 4
Withdrawn NCT01308502 - A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux Phase 4